+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032- Product Image
Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Amyotrophic Lateral Sclerosis Treatment Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305507
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Amyotrophic Lateral Sclerosis Treatment Market is projected to reach USD 816.08 Million in 2026. It is expected to continue growing at a CAGR of 7.38%, reaching USD 1.25 Billion by 2032.

Amyotrophic lateral sclerosis treatment is moving from primarily symptom management toward precision neurology, where disease-modifying drugs, respiratory care, nutrition, mobility support, communication support, and multidisciplinary clinics are coordinated around measurable patient outcomes. ALS is a progressive motor neuron disease with a typical survival of 2-5 years after symptom onset, although progression varies widely and a subset of patients live much longer.

The current treatment landscape is anchored by approved therapies such as riluzole, edaravone, and tofersen for SOD1-ALS, alongside noninvasive ventilation, gastrostomy support, speech-generating technology, rehabilitation, and palliative care. With approximately 5,000 new ALS diagnoses reported annually in the United States and global prevalence commonly reported at about 4-6 cases per 100,000 people, the market remains highly specialized, clinically urgent, and closely linked to rare disease innovation.

Transformative Shifts in the ALS Treatment Landscape

The ALS treatment landscape is being reshaped by genetically defined subgroups, biomarker-led trials, and a stronger regulatory focus on accelerated pathways for serious neurodegenerative diseases. The approval of a therapy for SOD1-ALS underscored the clinical and commercial importance of targeting molecular drivers rather than treating ALS as a single homogeneous condition.

Transformative shifts also include decentralized trial models, remote respiratory monitoring, digital speech and movement assessments, and expanded use of real-world evidence. Developers are increasingly investing in antisense oligonucleotides, neuroinflammation modulation, mitochondrial pathways, RNA biology, and gene-targeted approaches. These changes are improving trial design, patient stratification, and evidence generation in a disease where small populations and rapid progression historically constrained drug development.

Cumulative Impact of Artificial Intelligence on ALS Treatment

Artificial intelligence is increasingly influencing ALS treatment across diagnosis, trial recruitment, digital phenotyping, and biomarker discovery. Machine learning models can analyze electronic health records, speech recordings, wearable sensor outputs, imaging, genomics, and respiratory metrics to identify progression patterns that may not be visible through periodic clinical assessments alone.

The cumulative impact of AI is most evident in clinical development efficiency. AI-enabled patient matching can help identify eligible participants for rare genetic subtypes, while predictive analytics can support adaptive trial designs and reduce variability in outcome measurement. In care delivery, AI-assisted communication tools, voice banking, and remote monitoring platforms are improving continuity of care, although validation, privacy protection, bias control, and clinical oversight remain essential.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America leads ALS treatment adoption due to established neuromuscular centers, active patient registries, orphan drug incentives, and strong participation in clinical trials. The United States remains a core environment for approved ALS medicines, assistive technologies, multidisciplinary care, and advocacy-driven research funding, while Canada benefits from universal healthcare access and specialist networks, though provincial reimbursement timing can influence therapy uptake.

Europe shows strong clinical research capacity across Germany, France, Italy, Spain, and the United Kingdom, with European Union regulatory harmonization supporting cross-border studies, rare disease collaboration, and centralized medicine evaluation. Asia-Pacific is expanding through Japan’s long-standing experience with intravenous edaravone, China’s neurology infrastructure growth, India’s improving diagnostic capacity, South Korea’s advanced biopharma ecosystem, and Australia’s active rare disease research environment. Latin America, the Middle East, and Africa show rising ALS awareness but uneven access, with Brazil, Mexico, GCC countries, and South Africa serving as important care hubs where specialist availability, reimbursement systems, and diagnostic pathways shape treatment continuity.

Key Group Insights: G7, EU, BRICS, ASEAN, GCC & NATO

The G7 remains central to ALS treatment innovation because the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom combine advanced regulatory systems, clinical trial infrastructure, neuromuscular centers, and reimbursement pathways for high-cost orphan medicines. NATO countries overlap significantly with this innovation base and contribute to broader neurological research networks, data-sharing initiatives, rehabilitation technology adoption, and coordinated standards for advanced care delivery.

The European Union supports coordinated rare disease policy, centralized medicine evaluation, pharmacovigilance, and cross-border research collaboration, making it a key platform for ALS drug development and real-world evidence generation. BRICS countries, led by China, India, Brazil, and supported by expanding research activity in Russia and South Africa, are becoming increasingly important for patient population scale, clinical study participation, biosimilar and generic capabilities, and health system modernization. ASEAN and GCC markets are earlier in adoption but strategically relevant as specialist neurology services, medical tourism, digital health investment, and national rare disease programs expand across member countries.

Key Country Insights Across Major ALS Treatment Markets

The United States is the most influential ALS treatment environment, supported by orphan drug policy, the Accelerating Access to Critical Therapies for ALS Act, major academic centers, clinical trial networks, and advocacy-led funding. Canada follows with strong neuromuscular care networks and public coverage mechanisms, while Mexico and Brazil are improving access through public and private neurology services, although advanced therapies remain more dependent on reimbursement decisions, specialist availability, and diagnostic infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain active ALS research ecosystems, multidisciplinary care models, and participation in international clinical studies, while Russia’s access environment is more variable across regions and care settings. China and India are expanding diagnostic capacity, neurology services, and clinical research participation; Japan has deep experience with edaravone use and aging-related neurology demand; South Korea is investing in advanced biopharma and digital health; and Australia combines rare disease governance, specialist centers, and active clinical trial participation to support high-quality ALS care.

Actionable Recommendations for ALS Treatment Industry Leaders

Industry leaders should prioritize genetically stratified development programs, validated biomarkers, and patient-centered endpoints that reflect function, survival, speech, respiratory status, caregiver burden, and quality of life. Partnerships with ALS registries, academic neuromuscular centers, clinical trial networks, and advocacy organizations can improve recruitment, retention, genetic testing access, and real-world evidence quality.

Commercial strategies should account for the full ALS care continuum, not only drug therapy. Manufacturers, medtech developers, and digital health organizations can create value by integrating therapies with remote monitoring, assistive communication, respiratory support, nutrition management, rehabilitation, and home-based care. Early payer engagement, transparent evidence packages, post-approval data generation, and equitable access planning are critical for high-cost precision therapies in amyotrophic lateral sclerosis treatment.

Research Methodology for ALS Treatment Market Analysis

This executive summary is developed using a structured secondary and analytical research approach, drawing on verified information from regulatory agencies, public health organizations, peer-reviewed neurology literature, clinical trial registries, treatment guidelines, and recognized ALS advocacy and research institutions. Key evidence inputs include treatment approvals, disease epidemiology, orphan drug frameworks, trial activity, genetic testing relevance, biomarker development, and regional healthcare access indicators.

Insights are synthesized through cross-validation of clinical, regulatory, commercial, and geographic signals. The methodology emphasizes data integrity, source reliability, market relevance, and reproducibility. No unsupported market estimates are used; qualitative conclusions are grounded in observable treatment patterns, approved therapeutic options, documented disease burden, current clinical research activity, and validated innovation trends in ALS care.

Conclusion: Future of ALS Treatment Innovation

The amyotrophic lateral sclerosis treatment market is entering a decisive phase as precision medicine, AI-enabled research, and multidisciplinary care converge. While ALS remains a devastating and rapidly progressive disease, recent advances show that genetically targeted intervention, biomarker-driven development, and integrated supportive care can change the trajectory of therapeutic innovation.

Future progress will depend on earlier diagnosis, broader genetic testing, stronger real-world evidence, equitable reimbursement, and integrated care models that connect medicines with respiratory, nutritional, mobility, speech, and palliative support. Organizations that align clinical science with patient access, digital monitoring, and global collaboration will be best positioned to improve outcomes and compete effectively in this highly specialized neurodegenerative disease market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment
7.1. Introduction
7.2. Drug Type
7.2.1. Edaravone
7.2.2. Riluzole
7.3. Therapy
7.3.1. Gene Therapy
7.3.2. Stem Cell Therapy
8. Amyotrophic Lateral Sclerosis Treatment Market, by Type
8.1. Introduction
8.2. Familial ALS
8.3. Sporadic ALS
9. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage
9.1. Introduction
9.2. Early Stage Treatment
9.3. Mid Stage Treatment
9.4. Late Stage Treatment
10. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intrathecal
10.3. Intravenous
10.4. Oral
11. Amyotrophic Lateral Sclerosis Treatment Market, by Line Of Therapy Strategy
11.1. Introduction
11.2. First-Line
11.3. Targeted Therapy
11.4. Second-Line/Supportive Care
12. Amyotrophic Lateral Sclerosis Treatment Market, by Patient Age Group
12.1. Introduction
12.2. Juvenile & Young-Adult Onset
12.3. Late Onset
13. Amyotrophic Lateral Sclerosis Treatment Market, by Care Setting
13.1. Introduction
13.2. Inpatient Hospital
13.3. Outpatient Hospital
13.4. Specialty Clinics
13.4.1. Multidisciplinary ALS Clinics
13.4.2. Neurology Specialty Practices
13.5. Home Care
14. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel
14.1. Introduction
14.2. Online
14.3. Offline
15. Amyotrophic Lateral Sclerosis Treatment Market, by Region
15.1. Asia-Pacific
15.2. North America
15.3. Europe
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Amyotrophic Lateral Sclerosis Treatment Market, by Group
16.1. NATO
16.2. G7
16.3. European Union
16.4. BRICS
16.5. ASEAN
16.6. GCC
17. Amyotrophic Lateral Sclerosis Treatment Market, by Country
17.1. United States
17.2. China
17.3. Germany
17.4. Canada
17.5. Japan
17.6. Brazil
17.7. India
17.8. United Kingdom
17.9. Mexico
17.10. France
17.11. Italy
17.12. Australia
17.13. South Korea
17.14. Russia
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. Tanabe Pharma Corporation
19.2. Biogen Inc.
19.3. Novartis AG
19.4. Amylyx Pharmaceuticals, Inc.
19.5. Dewpoint Therapeutics, Inc.
19.6. Zydus Lifesciences Limited
19.7. Sun Pharmaceutical Industries Ltd
19.8. Otsuka Pharmaceutical Co., Ltd.
19.9. Sanofi SA
19.10. Teva Pharmaceutical Industries Ltd.
19.11. Viatris Inc.
19.12. Cipla Limited
19.13. F. Hoffmann-La Roche Ltd
19.14. GlaxoSmithKline PLC
19.15. AB Science SA
19.16. Alector, Inc.
19.17. Apotex Inc.
19.18. Aquestive Therapeutics, Inc.
19.19. AstraEureka Pharmaceuticals
19.20. BrainStorm Cell Limited
19.21. CorestemChemon Inc.
19.22. Coya Therapeutics, Inc.
19.23. Cytokinetics, Incorporated
19.24. DR. REDDY’S LABORATORIES LIMITED
19.25. Genervon Biopharmaceuticals, LLC
19.26. Implicit Bioscience Ltd.
19.27. Ionis Pharmaceuticals, Inc.
19.28. ITF Pharma, Inc.
19.29. Kringle Pharma, Inc.
19.30. Neurimmune AG
19.31. ONO PHARMACEUTICAL CO., LTD.
19.32. Orion Corporation
19.33. Orphazyme A/S
19.34. Pfizer, Inc.
19.35. Treeway B.V.
List of Figures
FIGURE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2032 (%)
FIGURE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DRUG TYPE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DRUG TYPE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DRUG TYPE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL EDARAVONE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL EDARAVONE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL EDARAVONE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RILUZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RILUZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RILUZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL FAMILIAL ALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL FAMILIAL ALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL FAMILIAL ALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL SPORADIC ALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL SPORADIC ALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SPORADIC ALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL EARLY STAGE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL EARLY STAGE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL EARLY STAGE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL MID STAGE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MID STAGE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MID STAGE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LATE STAGE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LATE STAGE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LATE STAGE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SECOND-LINE/SUPPORTIVE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SECOND-LINE/SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SECOND-LINE/SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL JUVENILE & YOUNG-ADULT ONSET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL JUVENILE & YOUNG-ADULT ONSET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL JUVENILE & YOUNG-ADULT ONSET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LATE ONSET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LATE ONSET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL LATE ONSET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL INPATIENT HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL INPATIENT HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INPATIENT HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL OUTPATIENT HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL OUTPATIENT HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OUTPATIENT HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL MULTIDISCIPLINARY ALS CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL MULTIDISCIPLINARY ALS CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MULTIDISCIPLINARY ALS CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL NEUROLOGY SPECIALTY PRACTICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL NEUROLOGY SPECIALTY PRACTICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL NEUROLOGY SPECIALTY PRACTICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 119. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 120. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 121. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 123. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 125. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 126. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 127. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 128. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 143. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 144. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 145. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 146. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 147. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 149. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 150. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 151. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 152. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 168. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 169. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 170. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 171. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 172. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 174. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 175. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 176. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 177. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 180. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 181. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 182. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 183. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 184. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 186. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 187. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 188. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 189. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 202. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 204. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 205. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 206. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 207. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 208. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 210. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 211. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 212. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 213. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 216. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 217. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 218. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 219. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 220. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 222. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 223. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 224. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 225. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 227. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 228. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 229. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 230. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 231. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 232. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 233. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 234. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 235. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 236. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 237. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 248. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 249. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 250. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 251. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 252. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 253. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 254. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 255. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 256. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 257. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 259. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 260. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 261. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 262. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 265. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 267. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 268. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 269. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 271. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 272. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 273. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 274. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 275. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 277. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 278. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 279. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 280. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 281. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 282. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 283. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 284. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 285. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 286. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 287. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 289. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 290. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 291. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 292. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 293. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 294. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 295. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 297. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 298. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2017-2032 (USD MILLION)
TABLE 303. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 304. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2017-2032 (USD MILLION)
TABLE 305. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 311. INDIA AMYOTROPHIC LA

Companies Mentioned

  • Tanabe Pharma Corporation
  • Biogen Inc.
  • Novartis AG
  • Amylyx Pharmaceuticals, Inc.
  • Dewpoint Therapeutics, Inc.
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • AB Science SA
  • Alector, Inc.
  • Apotex Inc.
  • Aquestive Therapeutics, Inc.
  • AstraEureka Pharmaceuticals
  • BrainStorm Cell Limited
  • CorestemChemon Inc.
  • Coya Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • DR. REDDY’S LABORATORIES LIMITED
  • Genervon Biopharmaceuticals, LLC
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Neurimmune AG
  • ONO PHARMACEUTICAL CO., LTD.
  • Orion Corporation
  • Orphazyme A/S
  • Pfizer, Inc.
  • Treeway B.V.

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 816.08 Million
Forecasted Market Value ( USD ) by 2032 $ 1250 Million
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned35

Related Topics

Related Reports

Amyotrophic Lateral Sclerosis Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Amyotrophic Lateral Sclerosis Treatment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 400 Pages
  • Global
From
Amyotrophic Lateral Sclerosis - Global Strategic Business Report - Product Image

Amyotrophic Lateral Sclerosis - Global Strategic Business Report

  • Report
  • 203 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Trends and Forecast by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region, 2026-2034 - Product Image

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Trends and Forecast by ALS Type, Drug Type, Diagnosis Type, Treatment, Distribution Channel, and Region, 2026-2034

  • Report
  • 138 Pages
  • Global
From
Amyotrophic Lateral Sclerosis Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Amyotrophic Lateral Sclerosis Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Amyotrophic Lateral Sclerosis (ALS) Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Amyotrophic Lateral Sclerosis (ALS) Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 89 Pages
  • Global
From

About the Amyotrophic Lateral Sclerosis Drug Market

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease. The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.